Professor James Uney
University of Bristol
Screening a neuroactive drug library to identify new treatments for Parkinson's
he drug company, Takeda has compiled an in-house multi-drug class library of 1000 novel compounds that cross the blood-brain-barrier. These unique drugs cannot be obtained elsewhere and are available to us through an existing collaboration with Takeda. Significantly, we will use this library in a high-throughput screen of mitochondrial function to identify drugs that are neuroprotective.
Promising therapeutic compounds will then be tested further using a dopaminergic neuron model of mitochondrial dysfunction and Parkinson’s disease.
This work is hence innovative, as it will screen a unique library to identify a drug and/or a class of drugs that that could ultimately be developed to protect against the loss of dopaminergic neurons associated with PD.